CancerDrs Find care

Brain Cancer clinical trials in Kentucky

10 actively recruiting brain cancer trials at 5 sites across Kentucky.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Kentucky:
  • Baptist Health Hardin — Elizabethtown, Kentucky
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
  • The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
  • Norton Brownsboro Hospital and Medical Campus — Louisville, Kentucky
  • UofL Health Medical Center Northeast — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…

Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Kentucky:
  • Baptist Health Lexington — Lexington, Kentucky
  • The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
  • UofL Health Medical Center Northeast — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
  • Norton Children's Hospital — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade g…

Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05566795
Sites in Kentucky:
  • Norton Children's Hospital — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…

Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Kentucky:
  • University of Kentucky Medical Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Kentucky:
  • Mercy Health - Paducah Medical Oncology and Hematology — Paducah, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
  • Norton Children's Hospital — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.

Sponsor: Giselle Sholler
NCT ID: NCT04696029
Sites in Kentucky:
  • Kentucky Children's Hospital — Lexington, Kentucky
  • Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine — Louisville, Kentucky
View on ClinicalTrials.gov →
Recruiting Academic/Other

Loupe-Based Intraoperative Fluorescence Imaging

Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary malignant brain tumors. Survival of patients with these brain tumors is directly related to the extent of resection. Consequently, a great deal of ef…

Sponsor: Guoqiang Yu
NCT ID: NCT04780009
Sites in Kentucky:
  • University of Kentucky — Lexington, Kentucky
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20